However, this approach has yielded limited success in NSCLC, as patients failed to mount an effective CD8+ T cell response, despite exhibiting humoral responses that stimulate CD4+ T cell activation [17–19]. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.